Cell Therapy News

An immunotherapy regimen featuring a novel chimeric antigen receptor T-cell therapy demonstrated antitumor activity against metastatic prostate cancer models, study results published in Nature Communications showed.

In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.

Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.

A single infusion of ALLO-316 provided a high rate of disease control for patients with advanced or metastatic renal cell carcinoma, results from the phase 1 TRAVERSE trial showed.

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

If Catherine M. Bollard, MD, grows tired of her day job as a physician and world-class cancer researcher, she can always fall back on her soprano singing capabilities.

Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.

A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.